Načítá se...
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
BACKGROUND: Synergistic cytotoxicity with high-dose statins and erlotinib has been demonstrated in preclinical models across a number of tumour types. In this phase I study, we evaluated the safety and potential anti-tumour activity of escalating doses of rosuvastatin in combination with the standar...
Uloženo v:
| Vydáno v: | J Transl Med |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4815068/ https://ncbi.nlm.nih.gov/pubmed/27036206 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0836-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|